VE-821 is a potent and selective ATP-competitive ATR (Ataxia-telangiectasia and Rad3-related protein) inhibitor, Ki=13 nM.1 Increases the sensitivity of pancreatic2 and ovarian3 cancer cells to radiation and chemotherapy. Increased replication stress induced by PARP inhibitors or chemotherapeutic agents increases sensitivity to VE-821 in neuroblastoma cells.4 Enhances the cytotoxicity of DNA damaging agents.5
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten